Literature DB >> 2910256

Plasma physostigmine concentrations after controlled-release oral administration.

L J Thal, B Lasker, N S Sharpless, G Bobotas, J M Schor, A Nigalye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2910256     DOI： 10.1001/archneur.1989.00520370015007

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  2 in total

Review 1.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.

Authors:  J R Atack; I Litvan; L J Thal; C May; S I Rapoport; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-09       Impact factor: 10.154
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.